## conferenceseries.com

## 13<sup>th</sup> Euro-Global Gastroenterology Conference

August 20-21, 2018 | Rome, Italy

Hepatotoxicity and related risk factors of severe hepatotoxicity among HIV-1 infected individuals initiated on highly active antiretroviral therapy (HAART) in Cameroon

Lem Edith Abongwa<sup>1,2,3</sup>, Anthony Kebira Nyamache<sup>2</sup>, Fokunang Charles<sup>4</sup>, Judith Torimiro<sup>3,4</sup>, Nshom Emmanuel<sup>5</sup>, Irénée Domkam<sup>3</sup> and Paul Okemo<sup>2</sup> <sup>1</sup>University of Bamenda, Cameroon

<sup>2</sup>Kenyatta University, Kenya

<sup>3</sup>Chantal Biya International Reference Center for Research on HIV/AIDS prevention and management, Cameroon

<sup>4</sup>University of Yaoundé I, Cameroon

<sup>5</sup>Mbingo Baptist Hospital – CBCHS, Cameroon

**Aims/Purpose:** Hepatotoxicity due to highly active antiretroviral therapy (HAART) has gained prominent attention since it can be affected by many factors. The aim of this study was to determine the prevalence of hepatotoxicity and related risk factors of severe hepatotoxicity following HAART initiation.

**Methods:** One hundred naive HIV-1 patients were recruited and followed up for 24 weeks. They were placed on either Tenofovir (TDF)+Lamivudine (3TC)+Efavirenz(EFV) or Zidovudine (AZT)+Lamivudine+Nevirapine (NVP) or Zidovudine+Lamivudine+Efavirenz regimen. Venous blood samples were collected to measure trans aminotransferases (ALT and AST) and alkaline phosphatase (ALP), using colometric enzymatic reaction which were used to classified hepatotoxicity based on age and sex.

**Results:** A total of 38 (38%) and 55 (55%) patients presented with hepatotoxicity while 15% and 28% of patients of them had severe hepatotoxicity at 4 and 24 weeks respectively. Serum levels of all enzymes increased significantly (p<0.05) with increased treatment duration. Univariate analysis revealed that the risk factor of developing severe hepatotoxicity was significantly (p<0.05) greater in patients <30 years, males, low BMI, low monthly income earners and patient on AZT+3TC+ NVP regimen. While multivariate analysis showed that age <30 years, Low BMI, low monthly income and the use of AZT+3TC+NVP was an independent risk factors.

**Conclusions:** Low BMI, <30years, low monthly income and the use of AZT+3TC+NVP regimen were identifiable risk factors for the development of severe hepatotoxicity. As such these factors should be considered as an important strategy by clinicians in preventing the hepatotoxicity.

## **Recent Publications:**

- 1. Lem E A et al. (2018) Incidence of elevated aminotransferases levels among patients presenting with hepatitis syndrome in the northwest region of Cameroon. Cohesive J. Microbiol. Infect. Dis. 1(1):1-5.
- 2. Lem E A et al. (2017) Knowledge, practice and prevalence of *Helicobacter pylori* infection in the north west region of Cameroon. Clinical Biotechnology and Microbiology. 1(4):135-143.
- 3. Lem E A et al. (2017) Hepatotoxicity and anaemia co-morbidity in treated HIV patients in Fundong subdivision in the northwest region of Cameroon. Microbiology Research Journal International. 18(5):1-10.
- 4. Lem E A, Nyuydzedze S S and Ndifor G A (2016) Assessment of knowledge, attitude and practice towards hepatitis B among two rural communities of the anglophone regions in Cameroon. IRA-International Journal of Applied Sciences. 4(3):490-505.
- Lem E A and Penn K (2016) Assessing prevalence and risk factors of hepatitis B surface antigen amongst pregnant women attending antenatal clinic in the northwest region of Cameroon. European Journal of Research in Medical Sciences. 4(1):32-43.

## Biography

Lem Edith Abongwa, a Medical Microbiologist is pursuing PhD from Kenyatta University, Kenya. She is also an Assistant Lecturer at the University of Bamenda, Cameroon. Her research interest is on HIV and Hepatitis B virus. She is interested in the identification and assessment of risk factors that expose communities to these infections and possible solutions to prevent and control them as well as parasite strain diversity and severity to infectious infection. Prior to medical research she was the Head of a public health non-governmental organization assessing the implementation of option B+ in two regions of Cameroon sponsored by a PEPFAR HIV/AIDS project in Cameroon.

lemedith19@gmail.com